Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Metastatic Non-Small Cell Lung Cancer
NCT00040768Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Apr 2002
- Primary completion
- Mar 2006
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Primary endpoint: Overall Response Rate at 4 years. Started Apr 2002; status: terminated.
02
Drugs
bortezomib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00040768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00040768.